|Rapid review complete
|For the treatment of children and adolescents from three years of age with growth disturbance due to insufficient secretion of growth hormone
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full HTA is not recommended. The NCPE recommends that somatrogon be considered for reimbursement*.
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement – November 2022.